Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLargo, Inc. filings document an operating company with cleantech, environmental engineering and life sciences subsidiaries, including disclosures tied to product and service revenue, partially owned subsidiaries, debt obligations and common stock. Registration statements and related exhibits describe common stock, capital structure, resale registration rights and equity financing arrangements.
BioLargo's Form 8-K filings record Regulation FD materials, investor presentation exhibits, annual operating-result releases, shareholder town hall transcripts, material definitive agreements and officer compensation converted into common stock. The filings also provide formal disclosure around governance, liquidity, subsidiary activity and risk factors associated with commercializing water treatment, medical technology, engineering services and energy-storage businesses.
BIOLARGO, INC. Chief Science Officer and director Kenneth Reay Code received a grant of 532,567 shares of common stock at an acquisition price of $0.1135 per share. The shares were issued by the company in exchange for reducing amounts owed to him for salary and unreimbursed business expenses.
The new award is subject to a Lock-Up Agreement that restricts any sale until the company reports at least $40 million of gross revenue on a consolidated basis for a reported period, its market capitalization exceeds $300 million, or there is a change in control. Following this grant, Code beneficially owns 26,408,319 shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
BIOLARGO, INC. President and director Dennis P. Calvert reported two stock awards that increased his direct holdings of common stock. On June 30, 2026 he acquired 699,569 shares at $0.1135 per share, and on July 1, 2026 he acquired 219,914 shares at $0.113 per share, both classified as grants or awards rather than open-market purchases.
The shares were issued by the company in exchange for reducing amounts it owed him for salary and unreimbursed business expenses. The awarded shares are subject to a Lock-Up Agreement, restricting sales until the company reports at least $40 million in consolidated gross revenue for any reported period, or its market capitalization exceeds $300 million, or there is a change in control. After these transactions, he directly owns 11,058,108 shares, which include 1,528,695 shares held indirectly through a limited liability company he owns and controls.
BIOLARGO, INC. director Jack B. Strommen received an option grant as part of his board compensation. He was granted options to purchase 132,159 shares of common stock at an exercise price of $0.1135 per share, expiring on June 30, 2036. After this grant, he holds options to purchase a total of 2,584,262 shares. The grant was issued in lieu of $15,000 in fees for his most recently completed quarterly board service under the company’s 2024 Equity Incentive Plan.
BioLargo director Linda Park received a stock option grant as board compensation. She was awarded options to purchase 165,198 shares of common stock at an exercise price of $0.1135 per share. After this grant, she holds options covering a total of 1,546,700 shares.
The option was issued in lieu of $18,750 in cash fees for her most recent quarterly board service, under BioLargo’s 2024 Equity Incentive Plan. This is a non-cash, compensation-related award rather than an open-market stock purchase or sale.
BioLargo director Christina Elaine Bray received a grant of options to purchase 165,198 shares of common stock. The options have an exercise price of $0.1135 per share and were granted as compensation for $18,750 in board fees for the most recently completed quarter under the 2024 Equity Incentive Plan.
Following this grant, she holds options covering a total of 1,546,700 shares. This is a compensation-related award rather than an open-market transaction.
BIOLARGO, INC. director Dennis E. Marshall reported two stock option grants on June 30, 2026. He received an option for 115,741 shares of common stock at an exercise price of $0.1135 per share, granted to replace a prior 22,500-share option that expired unexercised.
He also received a second option for 198,238 shares at the same $0.1135 exercise price as payment for $18,750 of board fees under the 2024 Equity Incentive Plan. Following these awards, his reported derivative holdings in options totaled 5,639,476 options.
BIOLARGO, INC. director Marshall Dennis E received a new stock option grant as part of his board compensation. On June 22, 2026, he was awarded options to purchase 40,909 shares of common stock at an exercise price of $0.11 per share, expiring June 22, 2036. The grant replaces a prior option for 10,000 shares that expired unexercised, and his total option holdings after this adjustment are 5,463,738 options.
BioLargo, Inc. reported Q1 2026 revenue of $1.115M, down sharply from $3.269M a year earlier, as product revenue fell from $2.803M to $577K. Service revenue rose modestly to $538K.
The company posted a net loss of $3.405M versus $1.921M in Q1 2025, driven by lower gross profit, higher operating expenses and increased interest and finance costs. Operating loss widened to $3.204M.
At March 31, 2026, BioLargo had cash and equivalents of $4.122M, current liabilities of $4.932M, and working capital of $513K, but total stockholders’ equity turned to a deficit of $187K. Management states that current-year gross profits will not fund operations and that these factors “raise substantial doubt” about the company’s ability to continue as a going concern without increased revenues and/or additional financing.
BioLargo, Inc. furnished a shareholder town hall transcript and investor summary describing progress and challenges across its five operating subsidiaries, without providing new formal financial results. CEO Dennis Calvert outlined strategic milestones, capital structure, and commercialization plans.
He said BioLargo’s market cap is about $50 million with roughly 320 million shares outstanding, and estimated subsidiary Clyra Medical at roughly $100 million, of which BioLargo owns 48% plus a 6% gross sales royalty. Recent milestones cited include a first municipal PFAS-removal installation in Lake Stockholm, New Jersey, a $1.2 million mineral-extraction engineering contract, new Clyra distribution deals including Al Hikma in MENA, and a memorandum of understanding with global water firm Aquatech for PFAS projects.
Calvert emphasized capital efficiency, stating about $50 million of invested capital has built five subsidiaries, two already commercial. He discussed the loss of Pooph-licensed odor-control revenue, ongoing litigation to protect intellectual property, and efforts to reposition that asset. He also highlighted the Cellinity sodium-based battery venture, describing long-life, non-degrading storage as a national-scale opportunity, and reiterated his view that the stock is undervalued as the company enters what he called a harvesting phase.
BioLargo, Inc. filed a current report announcing that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.
The town hall will feature a brief company update followed by a Q&A session with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day. The company also includes standard forward-looking statement and Safe Harbor language referencing risks described in its most recent SEC filings.
BioLargo, Inc. filed a current report announcing that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.
The town hall will feature a brief company update followed by a Q&A session with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day. The company also includes standard forward-looking statement and Safe Harbor language referencing risks described in its most recent SEC filings.